The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced ...

Short interest in InMed Pharmaceuticals Inc (NASDAQ:INM) increased during the last reporting period, rising from 40.01K to 115.52K. This put 0.87% of the company's publicly available shares short.

InMed Pharmaceuticals (INM) has filed to raise $10 million from the sale of common stock and warrants in an uplisting / Nasdaq IPO, according to an amended registration statement. Vancouver ...

INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that ...